(Q42997332)

12 November 2017

title

Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

1 reference

1 reference

12 November 2017

1 reference

12 November 2017

Giuseppe Pizzolanti

0 references

Vito Di Marco

0 references

Mariagrazia Rumi

0 references

Mario U Mondelli

0 references

Calogero Cammà

1 reference

12 November 2017

Danilo Di Bona

1 reference

12 November 2017

Ernesto Minola

1 reference

12 November 2017

Maria Vinci

1 reference

12 November 2017

Chiara Rebucci

1 reference

12 November 2017

Agostino Cividini

1 reference

12 November 2017

Massimo Colombo

1 reference

12 November 2017

Giovanbattista Pinzello

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

12 November 2017

1 reference

12 November 2017

1 reference

12 November 2017

1 reference

12 November 2017

page(s)

64-71

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

12 November 2017

cites work

1 reference

Hepatitis C virus core protein induces hepatic steatosis in transgenic mice

21 January 2018

1 reference

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

21 January 2018

1 reference

7 January 2021

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

7 January 2021

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

1 reference

7 January 2021

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

1 reference

7 January 2021

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

1 reference

7 January 2021

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

1 reference

7 January 2021

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

1 reference

7 January 2021

Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets

1 reference

7 January 2021

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

1 reference

7 January 2021

An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation

1 reference

7 January 2021

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

1 reference

7 January 2021

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

1 reference

7 January 2021

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

1 reference

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

1 reference

7 January 2021

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

1 reference

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

7 January 2021

Clinical significance of the insulin resistance index as assessed by homeostasis model assessment

1 reference

7 January 2021

Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease

1 reference

7 January 2021

Nonalcoholic steatohepatitis: definition and pathology

1 reference

7 January 2021

Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients

1 reference

7 January 2021

Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis

1 reference

7 January 2021

Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse.

1 reference

7 January 2021

Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity

1 reference

7 January 2021

Body fat distribution, relative weight, and liver enzyme levels: a population-based study.

1 reference

7 January 2021

Prospective Study of Serum -Glutamyltransferase and Risk of NIDDM

1 reference

7 January 2021

The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913.

1 reference

7 January 2021

Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index

1 reference

7 January 2021

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20983

1 reference

12 November 2017

1 reference